Viking Therapeutics
↗San Diego, USA
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. The company's research leverages expertise in metabolism to develop small molecule therapies that target large markets with significant unmet needs, such as obesity and non-alcoholic steatohepatitis (NASH/MASH).
The company is currently a high-profile player in the incretin space, developing dual GLP-1/GIP agonists that compete with established blockbusters from Eli Lilly and Novo Nordisk. Viking is also advancing programs in rare diseases like X-linked adrenoleukodystrophy (X-ALD).
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:$0 (Clinical Stage)
Founded:2012
Ownership:public
Status:operating
FUNDING
Stage:Public
Total Raised:$700M+
Investors:Voya Investment Management, BlackRock, Vanguard Group
STOCK
Exchange:NASDAQ
Ticker:VKTX
Market Cap:$3.7B
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3
Modalities:Small molecule, Peptide (GLP-1/GIP dual agonist), Oral tablet, Subcutaneous injection
Active Trials:4
Trial Phases:Phase 1: 1 | Phase 2: 1 | Phase 3: 2
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:CordenPharma (Multi-year manufacturing agreement for VK2735 API and finished product)
COMPETITION
Position:Challenger
Competitors:Eli Lilly (Zepbound/Mounjaro), Novo Nordisk (Wegovy/Ozempic), Madrigal Pharmaceuticals (Rezdiffra), Altimmune, Metsera (acquired by Pfizer)
LEADERSHIP
Key Executives:
Brian Lian, PhD - CEO
Greg Zante - CFO
Marianne Mancini - COO
Scientific Founders:Brian Lian
Board Members:Geoffrey Barker, Charles Nixon, Lawson Macartney
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Viking Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Viking Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.